Comparative Pharmacology
Head-to-head clinical analysis: IMPOYZ versus LEQSELVI.
Peer-Reviewed Evidence
Head-to-head clinical analysis: IMPOYZ versus LEQSELVI.
IMPOYZ vs LEQSELVI
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
IMPOYZ is a monoclonal antibody that binds to and inhibits the activity of interleukin-23 (IL-23), a cytokine involved in inflammatory and immune responses. By blocking IL-23, it reduces the production of pro-inflammatory cytokines and attenuates the inflammatory cascade.
LEQSELVI is a selective estrogen receptor degrader (SERD) that binds to estrogen receptors (ER), inducing their degradation and blocking ER-mediated signaling.
100 mg orally twice daily
LEQSELVI is not a recognized pharmaceutical name. No dosing information available.
None Documented
None Documented
Terminal elimination half-life 6–8 hours in adults with normal renal function; prolonged to 15–30 hours in severe renal impairment (CrCl <30 mL/min).
Terminal elimination half-life is approximately 12 hours in healthy adults; may be prolonged in patients with moderate to severe hepatic impairment.
Primarily renal (70–80% as unchanged drug via glomerular filtration and tubular secretion); biliary/fecal (15–20%) with minor hepatic metabolism.
Primarily excreted as unchanged drug via renal elimination (approximately 70% of dose), with biliary/fecal excretion accounting for about 20%.
Category C
Category C
Unknown
Unknown